Definitive External Beam Radiation Therapy With Stereotactic Body Radiation Therapy Boost for FIGO Stage IB - IIB Cancer of the Cervix: Minimum 5-Year Disease Control, Toxicity and Quality of Life Outcomes From a Phase 2 Trial Presenter: Constantine Mantz, MD – 21st Century Oncology Presentation No : 1237
11:20 AM - 11:25 AM
Stage III Uterine Serous Carcinoma: Improved Outcomes in the Modern Era with Multi-Modality Treatment Presenter: Jessie Li, BS – Yale University Presentation No : 1238
11:25 AM - 11:30 AM
Differential Effect of GLUT1 Overexpression on Survival and Tumor Immune Microenvironment of Human Papilloma Virus Type 16-Positive and -Negative Cervical Cancer Presenter: Ji Hyun Chang, MD – Seoul National University Hospital Presentation No : 1239
11:30 AM - 11:35 AM
Parametric Response Mapping of Co-Registered PET and Perfusion CT to Identify Radioresistant Sub-Volumes in Locally Advanced Cervical Carcinoma Presenter: Dante Capaldi, PhD Presentation No : 1240
11:35 AM - 11:40 AM
Targeting Aurora Kinase to Enhance the Curative Potential of Radiotherapy in HPV Related Cancers Presenter: Naz Chaudary, PhD – Princess Margaret Hospital Presentation No : 1241
11:40 AM - 11:45 AM
Regional Control and Dose-Response for Chemoradiotherapy in Locally-Advanced Endometrial Cancer Presenter: Uzoma Iheagwara, MD, PhD – UPMC Hillman Cancer Center Presentation No : 1242
11:45 AM - 11:50 AM
Posttreatment Squamous Cell Carcinoma Antigen in Predicting Treatment Failure for Patients with Cervical Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy Presenter: Weiping Wang Presentation No : 1243
11:50 AM - 11:55 AM
Utilizing the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated with Adjuvant Radiotherapy Presenter: Austin Prince, BS – University of South Florida Morsani College of Medicine Presentation No : 1244
11:55 AM - 12:00 PM
Dosimetric Analysis of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer in NRG Oncology's RTOG 1203 Presenter: Shalini Moningi, MD – MD Anderson Cancer Center Presentation No : 1245
12:00 PM - 12:05 PM
Comparison of Vaginal Microbiota in Gynecologic Cancer Patients Pre- and Post-Radiation Therapy and Healthy Women Presenter: Deborah Bruner, PhD, RN, FAAN – Emory University Presentation No : 1246
12:05 PM - 12:10 PM
Association Between CD4 Count and Chemoradiation Therapy Outcomes Among Cervical Cancer Patients with HIV Presenter: Priyanka Mehta, MPH – University of Texas Southwestern Medical Center Presentation No : 1247
12:10 PM - 12:15 PM
Discussant Discussant: Shruti Jolly, MD – University of Michigan
Disclosure: Employment Edward Hines VA Hospital: Radiation Oncologist: Employee; Loyola University Medical Center: Associate Professor of Radiation Oncology: Employee
Leadership Chicago Radiological Society: Radiation oncology program director and Trustee: Coordinate educational lecture series for our organization. Serve as a trustee and voting member of the board of directors.
Biography: Dr. Harkenrider is Associate Professor of Radiation Oncology, Medical Director, Residency Program Director, and Director of Brachytherapy at Loyola University Chicago in Chicago, Illinois. He serves on several committees within the U.S. National Cancer Institute Gynecologic Cancer Steering Committee including the Ovarian Cancer Task Force and Cervical Cancer Task Force. He serves on the Cervical Cancer and Lung Cancer Core Committees for NRG Oncology and works to develop clinical trials of novel multimodality therapy for the treatment of gynecologic and lung malignancies. He is active within the American Brachytherapy Society, serving as a faculty member for the ABS Annual Meeting and the ABS GYN School. Dr. Harkenrider is the Chair of the American College of Radiology HDR Brachytherapy Practice Parameter. He has published numerous peer-reviewed manuscripts with an emphasis on gynecologic brachytherapy and lung stereotactic body radiation therapy. He has also been active within the EMBRACE group and has worked extensively on delivering state-of-the-art treatment for locally advanced cervical cancer patients and developing and promoting MRI-based cervical brachytherapy.